Menopause, also termed as climacteric, refers to cessation of menstruation. It usually occurs in females aged between 45 and 55 years. Female infertility refers to a condition of infertility in females. Various causes for female infertility are polycystic ovary syndrome (PCOS), hypothalamic dysfunction, premature ovarian insufficiency, and hyperprolactinemia. Contraceptives are drugs and devices that are used to prevent pregnancy and sexually transmitted infections. Contraceptive drugs are further classified as contraceptive pills, topical contraceptives, and contraceptive injectables. The female infertility, menopause, and contraceptive drugs market is growing at a significant rate due to increasing disorders related to fertility and menopause and rising awareness about different menopause, female infertility and contraceptive drugs. In addition, government initiatives for improving female health are driving the market for female infertility, menopause, and contraceptive drugs.
North America dominates the global market for female infertility, menopause and contraceptive drugs due to the increasing prevalence of disorders related to menopause and female infertility in the region. In addition, high usage of contraceptive pills in the region due to the high efficiency provided by the drugs is driving the overall market for contraceptives. Asia, followed by Europe, is expected to experience high growth rate in the next few years in the female infertility, menopause, and contraceptive drugs market. China and India are expected to be the fastest growing female infertility, menopause, and contraceptive drugs markets in Asia. Some of the key driving forces for the female infertility, menopause and contraceptive drugs market in emerging countries are large pool of patients and rising government initiatives by funding and strict laws.
Increasing awareness about different disorders in female fertility, menopause, and complications in female health by not using birth control measures is contributing to the growth of the market for female infertility, menopause and contraceptive drugs. In addition, the increasing prevalence of female sexual disorders and improvement in healthcare facilities and technological advancements in the field have been driving the female infertility, menopause, and contraceptive drugs market. However, the side effects associated with the intake of contraceptive drugs and lower adoption rates for drugs associated with treatment of female infertility and menopause have been restraining the market.
Growing populations and developing economies in countries such as India and China are expected to offer good opportunities for the global female infertility, menopause, and contraceptive drugs market. The arrival on the market of some new products with better efficiency is expected to offer good opportunity for the global female infertility, menopause, and contraceptive drugs market. The growing number of mergers and acquisitions, new product launches, and increasing number of collaborations and partnerships are some of the latest trends that observed in the global female infertility, menopause and contraceptive drugs market. The side effects associated with intake of female infertility, menopause, and contraceptive drugs are a challenge for the market. Some of the major companies dealing in global menopause, fertility and contraceptive drugs market include Aventis SA, Bristol-Myers Squibb Company, Johnson & Johnson, and Merck & Company, Inc. Other significant players in the global menopause, fertility, and contraceptive drugs market include Novartis International AG, Bayers AG, Pharmacia & Upjohn, Inc., Organon, Inc., Berlex Laboratories, Parke-Davis, G. D. Searle & Company, TAP Holdings Inc., The Ares-Serono Group, and American Home Products Corporation.
Key geographies evaluated in this report are:
Key features of this report